Letters to the Editor

Follow this and additional works at: https://jdc.jefferson.edu/jeffjpsychiatry

Part of the Psychiatry Commons

Let us know how access to this document benefits you

Recommended Citation

DOI: https://doi.org/10.29046/JJP010.1.014
Available at: https://jdc.jefferson.edu/jeffjpsychiatry/vol10/iss1/15

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Jefferson Journal of Psychiatry by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Dear Editor:

The introduction of chlorpromazine in 1952 revolutionized the treatment of psychiatric disorders. By 1954 chlorpromazine had been linked to potential agranulocytosis (1). Over the last 37 years the risk to benefit ratio of the drug has been scrutinized. Chlorpromazine still remains the gold standard by which other antipsychotics must be judged.

We report the case of a 58 year old male with Bipolar Affective Disorder and Alcohol-induced Dementia who presented to the medical service with chest pain. Following evaluation of the patient’s symptoms and risk factors it was elected to perform cardiac catheterization. Prior to the catheterization a protime and partial thromboplastin time were performed. The PT was normal at 11.2 seconds; however the PTT was markedly elevated at 51.5 seconds. Additional laboratory work including CBC and numerical platelet count was unremarkable.

Hematology Service was consulted to evaluate the elevated PTT. They recommended mixing studies which were compatible with a coagulation inhibitor. A Russel’s Viper Venom Test was positive for a Lupus Antibody. The remainder of the hematology workup was negative and included RPR, ANA, ANA Antibody, and Rheumatoid Factor.

Psychiatric consultation was requested to determine if the patient’s psychotropic medication was effecting the coagulation studies. The patient was on chlorpromazine, lithium carbonate and clonazepam. His chlorpromazine was discontinued and an equivalent dose of haloperidol was begun. His PTT corrected within one week. Repeat PTT’s obtained at 2, 4, and 6 months were normal and no further abnormality was noted.

The lupus antibody is an IgM, or IgG immunoglobulin that produces a prolonged PTT by binding to the phospholipid used in the in vitro PTT assay. This laboratory artifact does not cause a clinical bleeding disorder. The lupus anticoagulant is seen in 5–10 percent of patients with Systemic Lupus Erythmatosus, but can be seen in patients on phenothiazines as with our patient. (2)

Lupus like syndromes have been induced by phenytoin, hydralazine, procainamide and isoniazid. The phenothiazines, thioxanthenes, butyrophenones and lithium have also been reported to induce ANA in some patients with chronic use. (3,4)

Zarrabi, in 1979 demonstrated that most long term patients on chlorpromazine developed immunologic abnormalities of significant IgM and prolongation of PTT. Fifty percent of these patients also developed spleenomegaly. (5)

Our purpose in writing this letter is to caution other clinicians that chlorpromazine can often produce an artifactual elevation in the PTT which is secondary to a circulating Lupus Antibody.

Acknowledgment

I would like to thank Deborah S. Claire R.N., B.S.N., for her administrative assistance.

52
The opinions in this paper are solely those of the authors and should not be construed as representative of the University of California at Davis or the Department of Veterans Affairs.

Robert Jay Claire, M.D.
Chief Resident in Psychiatry
East Bay Division of U.C. Davis at the Martinez, V.A.

Mark E. Servis, M.D.
Chief of the Consultation and Liaison Service
Martinez V.A. Medical Center

REFERENCES

1. P.D.R. 44th Edition page 2127
2. Current Medical Diagnosis and Treatment 1989, Lange page 338